Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients-Reference-Cited by-同舟云学术

Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tsolaki Vasiliki¹^ORCID,Mantzarlis Konstantinos¹,Mpakalis Athanasios¹,Malli Ergina²,Tsimpoukas Fotios³,Tsirogianni Athanasia³,Papagiannitsis Constantinos²,Zygoulis Paris¹,Papadonta Maria-Eirini¹,Petinaki Efthimia²,Makris Demosthenes¹,Zakynthinos Epaminondas¹

Affiliation:

1. Department of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece

2. Microbiology Department, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece

3. Intensive Care Unit, General Hospital of Lamia, Lamia, Greece

Abstract

Data on the effectiveness of ceftazidime-avibactam (CAZ-AVI) in critically ill, mechanically ventilated patients are limited. The present retrospective observational cohort study, which was conducted in two general intensive care units (ICUs) in central Greece, compared critically ill, mechanically ventilated patients suffering from carbapenem-resistant Enterobacteriaceae (CRE) infections receiving CAZ-AVI to patients who received appropriate available antibiotic therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02320-19

Reference30 articles.

1. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance

2. Redefining extended-spectrum -lactamases: balancing science and clinical need

3. European Centre for Disease Prevention and Control. 2018. Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae. European Centre for Disease Prevention and Control, Stockholm, Sweden.

4. Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence

5. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study;International Journal of Antimicrobial Agents;2024-09

2. Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan;International Journal of Antimicrobial Agents;2024-08

3. Clinical Experience with Ceftazidime/Avibactam for the Treatment of Extensively Drug-Resistant or Pandrug-Resistant Klebsiella pneumoniae in Neonates and Children;2024-07-08

4. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

5. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis;Infectious Diseases and Therapy;2024-05-31